|
gptkbp:instance_of
|
gptkb:biotechnology
|
|
gptkbp:academic_programs
|
Ms. Mary Pink
|
|
gptkbp:acquisition
|
gptkb:C5_Therapeutics
gptkb:Synageva_Bio_Pharma
Wilson Therapeutics
|
|
gptkbp:advertising
|
gptkb:Dr._David_Hallal
gptkb:Ms._Jane_Doe
gptkb:Mr._John_Smith
Ms. Nancy Brown
|
|
gptkbp:ceo
|
gptkb:David_Hallal
|
|
gptkbp:clinical_trial
|
Phase 3 trials
Phase 1 trials
Phase 2 trials
|
|
gptkbp:conducts_research_on
|
gptkb:Dr._John_Orloff
|
|
gptkbp:focus
|
rare diseases
|
|
gptkbp:founded
|
gptkb:2000
|
|
gptkbp:founder
|
gptkb:Leonard_Bell
|
|
gptkbp:has_authority_over
|
gptkb:Mr._Richard_Roe
|
|
gptkbp:head
|
Mr. Tom Brown
|
|
gptkbp:head_of_market_access
|
Mr. James Cyan
|
|
gptkbp:head_of_pharmacovigilance
|
Ms. Laura Purple
|
|
gptkbp:head_of_state
|
gptkb:Dr._Robert_Orange
gptkb:Ms._Karen_Magenta
gptkb:Ms._Emily_White
gptkb:Mr._Brian_Teal
gptkb:Ms._Lisa_Blue
gptkb:Ms._Sarah_Green
|
|
gptkbp:headquarters
|
gptkb:Cambridge,_Massachusetts
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
ALXN
|
|
gptkbp:investment
|
gptkb:Mr._Paul_Gray
|
|
gptkbp:number_of_employees
|
~3,000
|
|
gptkbp:partnership
|
gptkb:Bristol-Myers_Squibb
gptkb:Horizon_Therapeutics
gptkb:Amgen
gptkb:Abb_Vie
Sobi
|
|
gptkbp:product
|
gptkb:Soliris
gptkb:Ultomiris
gptkb:Crysvita
Strensiq
|
|
gptkbp:provides_training_for
|
gptkb:Mr._Kevin_Gold
|
|
gptkbp:public_relations
|
Ms. Anna Yellow
|
|
gptkbp:regulatory_compliance
|
Mr. Mark Black
Ms. Rachel Silver
|
|
gptkbp:research_focus
|
metabolic disorders
neurological disorders
complement inhibition
|
|
gptkbp:risk_management
|
Mr. Eric Bronze
|
|
gptkbp:stock_symbol
|
gptkb:ALXN
|
|
gptkbp:strategic_goals
|
Ms. Julia Gray
|
|
gptkbp:supply_chain
|
gptkb:Mr._Steve_Red
|
|
gptkbp:traded_on
|
gptkb:NASDAQ
|
|
gptkbp:website
|
www.alexion.com
|
|
gptkbp:bfsParent
|
gptkb:Alexion_Pharmaceuticals
|
|
gptkbp:bfsLayer
|
5
|